Adenoviral Mediated Interferon-α 2b Gene Therapy Suppresses the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Superficial Bladder Cancer

Adam, Liana; Black, Peter C.; Kassouf, Wassim; Eve, Beryl Y.; McConkey, David J.; Munsell, Mark F.; Benedict, William F.; Dinney, Colin P.

doi:10.1016/j.juro.2007.01.003

Cited by 19 publications

(9 citation statements)

References 17 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For BC, an oncolytic virus (CG0070) destroying retinoblastoma (RB) pathway defective cells armed with GM-CSF was used for the treatment of recurrent NMIBC. [59] Of 35 patients, 13 had received single dose (up to 3x 10 3 virus particles); whereas the remaining 22 (28 days x 3 or weekly x6) patients had multiple doses. The authors reported that urine GM-CSF peaked in the second day of the treatment in 94.3% of the patients; which is correlated with the dose administered.…”

Section: Future Conceptsmentioning

confidence: 99%

Alternative therapies in patients with non-muscle invasive bladder cancer

Şanlı

Lotan

2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required. Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients. For these patients, some treatment options are readily available and a variety of them are currently under clinical investigation. In this review, these alternative therapies have been summarized.

show abstract

Section: Future Conceptsmentioning

confidence: 99%

Alternative therapies in patients with non-muscle invasive bladder cancer

Şanlı

Lotan

2017

Turkish Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Non-replicating vectors such as lentivirus (Kikuchi et al , 2004; Adam et al , 2007), adenovirus (Werthman et al , 1996; Sutton et al , 2000) and poxviruses (Fodor et al , 2005) have shown strong therapeutic gene expression in bladder cancer including endostatin (Shichinohe et al , 2001) and p53 (Ruifa et al , 2006). Oncolytic viruses such as retroviral (RCR) vectors (Kikuchi et al , 2007), adenovirus (Wang et al , 2006), VSV (Hadaschik et al , 2008), reovirus (Hanel et al , 2004), vaccinia virus (Fodor et al , 2005) and HSV-1 (Cozzi et al , 2001) offer bladder tumour selective killing due to viral replication and even stronger therapeutic gene expression due to multiple rounds of replication and promoter upregulation (Hadaschik et al , 2008).…”

Section: Discussionmentioning

confidence: 99%

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer

et al. 2012

View full text Add to dashboard Cite

Background:There are still no effective treatments for superficial bladder cancer (SBC)/non-muscle invasive bladder cancer. Following treatment, 20% of patients still develop metastatic disease. Superficial bladder cancer is often multifocal, has high recurrences after surgical resection and recurs after intravesical live Bacillus Calmette–Guérin. OncovexGALV/CD, an oncolytic herpes simplex virus-1, has shown enhanced local tumour control by combining oncolysis with the expression of a highly potent pro-drug activating gene and the fusogenic glycoprotein.Methods:In vitro fusion/prodrug/apoptotic cell-based assays. In vivo orthotopic bladder tumour model, visualised by computed microtomography.Results:Treatment of seven human bladder carcinoma cell lines with the virus resulted in tumour cell killing through oncolysis, pro-drug activation and glycoprotein fusion. OncovexGALV/CD and mitomycin C showed a synergistic effect, whereas the co-administration with cisplatin or gemcitabine showed an antagonistic effect in vitro. Transitional cell cancer (TCC) cells follow an apoptotic cell death pathway after infection with OncovexGALV/CD with or without 5-FC. In vivo results showed that intravesical treatment with OncovexGALV/CD + prodrug (5-FC) reduced the average tumour volume by over 95% compared with controls.Discussion:Our in vitro and in vivo results indicate that OncovexGALV/CD can improve local tumour control within the bladder, and potentially alter its natural history.

show abstract

“…Any cytokine that tilts the TH1/TH2 balance in favor of a TH1 response may induce tumor regression. It was recently reported that tilting the TH1/TH2 balance may block the immune suppression of CD8 T cells by mononuclear phagocytes [47, 48]. Better therapeutic responses could be induced by not only inducing TH1 responses but also concurrently suppressing TH2 responses.…”

Section: Discussionmentioning

confidence: 99%

Tumor and Microenvironment Modification during Progression of Murine Orthotopic Bladder Cancer

Tham

Pook

et al. 2011

Clinical and Developmental Immunology

View full text Add to dashboard Cite

The aim of this study was to monitor changes in the expression of immune-related genes in the bladder after tumor implantation. Mice were orthotopically implanted with MB49-PSA cells (C57BL/6 mice) on day 1 and terminated on days 7, 14, 21, and 28. Another mouse model (MBT-2/C3H mice) was examined at day 7. Gene expression analysis was performed using a TaqMan Low Density Mouse Immune Panel (Applied Biosystems, USA) on RNA extracted from the bladders. Selected genes were reconfirmed by real-time PCR analysis and RT-PCR on the mRNA from other animals. Immune suppressive (IL13, IL1β, PTGS2, NOS2, IL10, CTLA4, and CCL22) and immune stimulatory genes (CSF2, GZMB, IFNγ, CXCL10, TNFα, CD80, IL12a, and IL6) and AGTR2 were increased by day 7. By day 28, IL10, CCL2, CCL5, CXCL11, CTLA4, GZMB, IFNγ, CSF2, and IL6 were significantly increased. Therapeutic strategies involving TH1 induction and TH2 dampening may improve responses to immunotherapy.

show abstract

Adenoviral Mediated Interferon-α 2b Gene Therapy Suppresses the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Superficial Bladder Cancer

Cited by 19 publications

References 17 publications

Alternative therapies in patients with non-muscle invasive bladder cancer

Alternative therapies in patients with non-muscle invasive bladder cancer

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer

Tumor and Microenvironment Modification during Progression of Murine Orthotopic Bladder Cancer

Contact Info

Product

Resources

About